CG Oncology Inc. (CGON) — Financial statements
Income statement, balance sheet, and cash flow for CG Oncology Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 4↑254.7% | 1↑458.3% | 0.20↑6.8% | 0.19↓98.2% | 10 | |
| Cost of Revenue | 5 | 0.00 | 0.00↓100.0% | 0.02↑50.0% | 0.01 | |
| Gross Profit | -0.61↓153.3% | 1↑458.3% | 0.20↑15.9% | 0.18↓98.3% | 10 | |
| Operating Expenses | ||||||
| R&D Expenses | 117↑42.1% | 82↑79.5% | 46↑57.6% | 29↑58.5% | 18 | |
| General & Administrative Expenses | 74↑118.2% | 34↑240.4% | 10↑54.5% | 6↑38.0% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↑100.0% | -0.02↓50.0% | -0.01 | |
| SG&A Expenses | 74↑118.2% | 34↑240.4% | 10↑54.9% | 6↑37.9% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 190↑64.2% | 116↑108.1% | 56↑57.1% | 35↑54.3% | 23 | |
| Total Costs & Expenses | 195↑68.2% | 116↑108.1% | 56↑57.0% | 35↑54.3% | 23 | |
| Operating Results | ||||||
| Operating Income | -191↓66.4% | -115↓106.8% | -55↓57.3% | -35↓179.6% | -13 | |
| Depreciation & Amortization | 1↑4415.6% | 0.03↑88.2% | 0.02↑13.3% | 0.02↑50.0% | 0.01 | |
| EBITDA | -160↓39.2% | -115↓106.8% | -55↓57.3% | -35↓184.6% | -12 | |
| EBIT | -161↓40.4% | -115↓106.8% | -55↓57.3% | -35↓184.5% | -12 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 27↑285.6% | 7↑690500.0% | -0.00↑99.8% | -0.45 | |
| Interest Income | 0.00↓100.0% | 27↑285.6% | 7 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.00↓99.8% | 0.45 | |
| Non-Operating Income | -30 | 0.00 | 0.00 | 0.00↑100.0% | -0.22 | |
| Other Income / Expenses | 30↑11.8% | 27↑289.2% | 7↑3573.1% | -0.20↑15.5% | -0.23 | |
| Income Before Tax | -161↓82.9% | -88↓81.1% | -49↓37.1% | -35↓176.1% | -13 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -161↓82.9% | -88↓81.1% | -49↓37.1% | -35↓176.1% | -13 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -161↓82.9% | -88↓81.1% | -49↓37.1% | -35↓176.1% | -13 | |
| Bottom-Line Net Income | -161↓82.9% | -88↓29.9% | -68↓54.8% | -44↓138.2% | -18 | |
| EPS (Basic) | -2.08↓47.5% | -1.41↓38.2% | -1.02↓54.5% | -0.66↓135.7% | -0.28 | |
| EPS (Diluted) | -2.08↓47.5% | -1.41↓38.2% | -1.02↓54.5% | -0.66↓135.7% | -0.28 | |
| Weighted Average Shares | 77↑23.7% | 62↓6.2% | 67↑0.0% | 67↑0.0% | 67 | |
| Weighted Average Diluted Shares | 77↑23.7% | 62↓6.2% | 67↑0.0% | 67↑0.0% | 67 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.